BradfordRichardHirschMDMBA

Oncology • Dallas, TX

Genitourinary Oncology, Hematologic Oncology

Senior Medical Director at Flatiron Health

Join to view full profile

Dr. Hirsch is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hirsch's full profile

Already have an account?

Office
7777 Forest Ln
Ste D400
Dallas, TX 75230
Phone+1 972-566-7790

Fax+1 972-566-7996
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
University of Texas Southwestern Medical SchoolClass of 2006

Certifications & Licensure

TX State Medical License 2014 - 2021
NC State Medical License 2012 - 2015

Publications & Presentations

PubMed

6 citations
Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence.
George Tran, Matthew Harker, Karen Chiswell, Joseph M. Unger, Mark E. Fleury, Bradford R. Hirsch, Kimberly D. Miller, Philip D'Almada, Sheri Tibbs, S. Yousuf Zafar> ;JCO Clinical Cancer Informatics. 2020 Jan 24
8 citations
Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Anne M. Butler, Karynsa Cetin, Rohini K. Hernandez, B. Diane Reams, Robert A. Overman, Jung In Kim, Bradford R. Hirsch, Amy P. Abernethy, Alexander Liede, M. Alan Broo...> ;Pharmacoepidemiology and Drug Safety. 2018 Feb 1
5 citations
Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell C...
Nrupen A. Bhavsar, Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, S. Wolf, Greg Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, Daniel J. George> ;Cancer Investigation. 2017 Apr 3
131 citations
Surgical Prehabilitation in Patients with Cancer: State-of-the-Science and Recommendations for Future Research from a Panel of Subject Matter Experts
Francesco Carli, Julie K. Silver, Liane S. Feldman, Andrea B. McKee, Sean Gilman, Chelsia Gillis, Celena Scheede-Bergdahl, Ann Gamsa, Nicole L. Stout, Bradford R. Hirsch> ;Physical Medicine and Rehabilitation Clinics of North America. 2017 Feb 1
10 citations
Experience of the National Cancer Institute Community Cancer Centers Program on Community-Based Cancer Clinical Trials Activity.
Bradford R. Hirsch, Susan C. Locke, Amy P. Abernethy> ;Journal of Oncology Practice. 2016 Mar 29
29 citations
Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors
Geoffrey R. Oxnard, Katharine H. Wilcox, Mithat Gonen, Mikhael Polotsky, Bradford R. Hirsch, Lawrence H. Schwartz> ;JAMA Oncology. 2016 Jun 1
4 citations
Sequential Therapy in Metastatic Renal Cell Carcinoma.
Hirsch, B. R., Burke, J. M., Agrawal, M., Hauke, R. J., Hutson, T. E., Doshi, G., Fleming, M. T., Vogelzang, N. J.> ;Journal of kidney cancer and VHL. 2016 Jan 1
67 citations
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Aaron P. Mitchell, Michael R. Harrison, Mark S. Walker, Daniel J. George, Amy P. Abernethy, Bradford R. Hirsch> ;Journal of Oncology Practice. 2015 Sep 1
60 citations
Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention
Connie N. Hess, Matthew T. Roe, Robert M. Clare, Karen Chiswell, Kelly Joseph M, James E. Tcheng, Emil Hagström, Stefan James, Michel G. Khouri, Bradford R. Hirsch, Da...> ;Journal of the American Heart Association. 2015 Jul 6
15 citations
Deferred systemic therapy in patients with metastatic renal cell carcinoma.
Aaron P. Mitchell, Bradford R. Hirsch, Michael R. Harrison, Amy P. Abernethy, Daniel J. George> ;Clinical Genitourinary Cancer. 2015 Jun 1
69 citations
Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Michaela A. Dinan, Xiaojuan Mi, Shelby D. Reed, Bradford R. Hirsch, Gary H. Lyman, Lesley H. Curtis> ;JAMA Oncology. 2015 May 1
36 citations
Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value
Michaela A. Dinan, Bradford R. Hirsch, Gary H. Lyman> ;Journal of the National Comprehensive Cancer Network. 2015 Jan 1
18 citations
Biosimilars: a cure to the U.S. health care cost conundrum?
Bradford R. Hirsch, Gary H. Lyman> ;Blood Reviews. 2014 Nov 1
36 citations
The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs
Bradford R. Hirsch, Suresh Balu, Kevin A. Schulman> ;Health Affairs. 2014 Oct 1
6 citations
Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.
Bradford R. Hirsch, Michael R. Harrison, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward J. Stepanski, Amy P. Abernethy> ;Medical Oncology. 2014 Aug 14
41 citations
Assessing The Value Of Patient-Generated Data To Comparative Effectiveness Research
Lynn Howie, Bradford R. Hirsch, Tracie D. Locklear, Amy P. Abernethy> ;Health Affairs. 2014 Jul 1
10 citations
Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
Aaron P. Mitchell, Bradford R. Hirsch, Amy P. Abernethy> ;Trials. 2014 Mar 25
1 citations
Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward?
Bradford R. Hirsch, Daniel J. George, Michael R. Harrison> ;Clinical Advances in Hematology & Oncology. 2014 Mar 1
25 citations
Real-World Outcomes in Metastatic Renal Cell Carcinoma: Insights From a Joint Community-Academic Registry
Michael R. Harrison, Bradford R. Hirsch, Daniel J. George, Mark S. Walker, Connie Chen, Beata Korytowsky, Edward J. Stepanski, Amy P. Abernethy> ;Journal of Oncology Practice. 2014 Mar 1
1 citations
Comparative Effectiveness Research: Moving Medical Oncology Forward
Bradford R. Hirsch, S. Yousuf Zafar> ;Seminars in Radiation Oncology. 2014 Jan 1
9 citations
A comparison of FDA and EMA drug approval: implications for drug development and cost of care.
Lynn Howie, Bradford R. Hirsch, Amy P. Abernethy> ;Oncology. 2013 Dec 15
20 citations
Will biosimilars gain momentum
Bradford R. Hirsch, Gary H. Lyman> ;Journal of the National Comprehensive Cancer Network. 2013 Oct 1
The ethics of health information technology in oncology: emerging isssues from both local and global perspectives.
Leblanc TW Shulman LN Yu PP Hirsch BR Abernethy AP> ;Am Soc Clin Oncol Educ Book. 2013
135 citations
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov.
Bradford R. Hirsch, Robert M. Califf, Steven K. Cheng, Asba Tasneem, John R. Horton, Karen Chiswell, Kevin A. Schulman, David M. Dilts, Amy P. Abernethy> ;JAMA Internal Medicine. 2013 Jun 10
3 citations
Incorporating the patient's voice in the continuum of care.
Bradford R. Hirsch, Amy P. Abernethy> ;Journal of the National Comprehensive Cancer Network. 2013 Jan 1
Join now to see all